8-K: Ainos Inc. Expands Product Development Agreement with Taiwan Carbon Nano Technology

Ainos Inc. has entered into an addendum to its existing product development agreement with Taiwan Carbon Nano Technology Corporation, outlining new co-development projects and associated costs.

Summary

• Ainos, Inc. has modified its existing product development agreement with Taiwan Carbon Nano Technology Corporation (TCNT).
• The addendum, effective January 9, 2024, expands the scope of co-development to include VOC diagnostics, AI Nose and POCT mass production, and other products.
• TCNT will provide facilities, equipment, and mass production support, excluding raw material procurement and utility costs.
• Ainos will pay TCNT a total of NT$5 million (approximately USD$161,000) for five years of development starting in 2024.
• For six months starting January 2024, Ainos will pay US$95,000 per month (plus 5% sales tax) for non-exclusive use of certain patents related to VOC and POCT technologies.

Sentiment

Score: 7

Explanation: The agreement is a positive step for Ainos, expanding its product development pipeline, but it also involves significant costs and risks.

Positives

• The addendum expands the scope of the product development agreement, potentially leading to new revenue streams.
• TCNT will provide significant support for mass production, reducing Ainos's operational burden.
• The agreement includes access to key patents for VOC and POCT technologies.
• The cost of the five-year development is fixed at NT$5 million, providing cost certainty.

Negatives

• Ainos will incur a monthly cost of US$95,000 (plus 5% sales tax) for six months for non-exclusive patent use.
• The agreement excludes the cost of raw materials, rental fees, and utilities, which Ainos will need to cover separately.

Risks

• The success of the co-developed products is not guaranteed.
• The cost of raw materials, rental fees, and utilities could be higher than anticipated.
• The non-exclusive patent license may limit Ainos's competitive advantage.
• Negotiations for subsequent use of the patents may not be successful.

Future Outlook

The agreement outlines a five-year co-development plan with TCNT, with potential for further patent licensing negotiations after the initial six-month period.

Management Comments

• The company's audit committee ratified the Original Agreement and approved the Addendum Agreement on January 8, 2024.

Industry Context

This agreement reflects a trend in the biotech and medical device industries towards collaborative product development to leverage expertise and resources.

Comparison to Industry Standards

• The agreement is similar to other co-development agreements in the biotech industry, where companies share costs and resources to develop new products.
• The patent licensing terms are typical for early-stage technology access, with options for further negotiation.
• The fixed development fee provides cost certainty, which is a common practice in such agreements.

Related Party Transactions

• The agreement is with Taiwan Carbon Nano Technology Corporation (TCNT), an affiliate company.

Stakeholder Impact

• Shareholders may view this agreement positively as it expands the company's product pipeline.
• Employees involved in product development will be impacted by the new projects.
• Customers may benefit from the new products developed through this agreement.
• Suppliers may see increased demand for raw materials.

Next Steps

• Ainos and TCNT will begin co-developing the products outlined in the addendum.
• Ainos will make monthly payments for the non-exclusive patent license.
• The parties will negotiate subsequent use of the patents after the initial six-month period.

Key Dates

Keywords

Product Development, Co-development, Pharmaceuticals, Medical Devices, VOC Diagnostics, AI Nose, POCT, Patents, Manufacturing, Taiwan Carbon Nano Technology